<DOC>
	<DOC>NCT02647918</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis (HD), on the safety and tolerability of 1 or 2 single doses of sotagliflozin compared with healthy, demographically-matched subjects with normal renal function.</brief_summary>
	<brief_title>Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Adult male and female subjects ≥18 to ≤75 years of age Body mass index ≥18.0 to ≤36.0 kg/m2, at Screening Subjects with mild, moderate, or severe renal impairment, or ESRD requiring HD Control group of matched healthy subjects Willing and able to provide written informed consent Presence of clinically significant physical, laboratory, or ECG findings that may interfere with any aspect of study conduct or interpretation of results Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of sotagliflozin History of any major surgery within 6 months History of hepatic disease, or significantly abnormal liver function test Women who are breastfeeding or are planning to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>